Ahmed Shelbaya
4PUBLICATIONS
18CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (4)
Sort by Publication Date:
|Oct 30, 2025
Characterization of Second-Line Therapy After First JAK Inhibitor Use: Results From the CorEvitas Rheumatoid Arthritis Registry.Joshua F Baker, Kristi V Mizelle, Wassim Saikali
|Dec 20, 2024
Effectiveness of tofacitinib versus tumor necrosis factor inhibitors and in those receiving tofacitinib as different lines of therapy in patients with rheumatoid arthritis: results from the United States CorEvitas Rheumatoid Arthritis Registry.Leslie R Harrold, Clifton O Bingham, Janet E Pope
|May 20, 2024
Clinical and Economic Value of a Biosimilar Portfolio to Stakeholders: An Integrative Literature Review.Grace E Fox, Mark Bernauer, Jennifer M Stephens
|Jul 14, 2021
Real-world use and acceptance of biosimilar monoclonal antibodies of rituximab in oncology practice in the USA.Ahmed Shelbaya, John M Kelton, Jeffrey Thompson
Pageof 1
Frequent Collaborators
1 joint publications
Martine C Maculaitis
1 joint publications
Jingyan Yang
1 joint publications
Grace E Fox
1 joint publications
Mark Bernauer
1 joint publications
Jennifer M Stephens
1 joint publications
Bianca Jackson
1 joint publications
Joshua A Roth
1 joint publications
Leslie R Harrold
1 joint publications
Janet E Pope
1 joint publications
Karim R Masri
